Galmed Pharmaceuticals Ltd. (GLMD)’in fiyatı nedir?

Galmed Pharmaceuticals Ltd. (GLMD)’in fiyatı $0.5225’dir

Galmed Pharmaceuticals Ltd. (GLMD)’in piyasa değeri nedir?

Galmed Pharmaceuticals Ltd. (GLMD)’in piyasa değeri $4.32M’dir.

Galmed Pharmaceuticals Ltd. (GLMD) Hisse Bölünmeleri

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Yıl	Bölünme	Çarpan	Kümülatif Çarpan
Sağlanan tarihler için yeterli veri yok.

Yıl

Bölünme

Çarpan

Kümülatif Çarpan

Sağlanan tarihler için yeterli veri yok.

Şirket	Hisse bölünme sayısı	Kümülatif Çarpan	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Şirket

Hisse bölünme sayısı

Kümülatif Çarpan

Ülke